Novartis raises blockbuster drug forecasts to $18 billion as it seeks to prove growth can last

The Quick Take
The drugmaker cited strong demand for its blockbuster drugs as it upgraded peak sales forecasts for multiple sclerosis, leukemia, and cholesterol medicines.
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to CNBC Top News.
Related
Markets
Full Truck Alliance declares $0.084/ADS dividend
Markets
My wife pays thousands of dollars for her family to visit from Argentina. How can I convince her to stop?
“I don’t want my wife to feel that I’m asking her to choose between me and her family.”
Markets
Why is Universal Technical Institute stock sliding today?
Markets
